60
Views
13
CrossRef citations to date
0
Altmetric
Original Article

The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus

, , &
Pages 659-666 | Received 29 Nov 2011, Accepted 14 Jun 2012, Published online: 02 Jan 2014

REFERENCES

  • Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983;309:1094–104.
  • Braun J, Rau R. An update on methotrexate. Curr Opin Rheum. 2009;21:216–23.
  • Rothenberg RJ, Graziano FM, Grandone JT, Goldenberg JW, Bjamason DF, Finesilver AG. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum. 1988;31:612–5.
  • Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1994;21:1674–7.
  • Wise CM, Vuyyuru S, Roberts WN. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease-a review of 36 patients. J Rheumatol. 1996;23: 1005–10.
  • Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol. 1998;25:243–6.
  • Carneiro JRM, Sato EL. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus ery-thematosus. J Rheumatol. 1999;26:1275–9.
  • Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630–40.
  • Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Meth-otrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis. 1997;56:382–5.
  • Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blinded, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59:1796–804.
  • Schur PH, Swanson J. Immunologic factors and clinical activity in systemic erythematosus. N Engl J Med. 1968;278:533–8.
  • Lloyd W, Schur PH. Immune complexes, complement, and anti-dsDNA in exacerbations of systemic lupus erythematosus (SLE). Medicine. 1981;60:208–17.
  • Swaak MG, Gorenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythe-matosus. Ann Rheum Dis. 1986;45:359–66.
  • Sullivan KE, Wisnieski JJ, Winkelstein JA, Louie J, Sachs E, Choi R, et al. Serum complement determinations in patients with quiescent systemic lupus erythematosus. J Rheumatol. 1996;23: 2063–7.
  • Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum. 1983;25:1271–7.
  • Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observation cohort (IORRA). Mod Rheumatol. 2007;17:98–105.
  • Glantz SA. Primers of biostatistics. 5th ed. NY: McGraw-Hill, Inc. Health Professions Division; 2002. p. 89–90.
  • Ravelli A, Ballardini G, Viola S, Villa I, Ruperto N, Martini A. Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. J Rheumatol. 1998;25:572–5.
  • Galarza D, Esquivel J, Villarreal M, de la Garza N, Garza M. Methotrexate in lupus nephritis: an uncontrolled study, preliminary results. Arthritis Rheum. 1992;34;187 (abstract D140).
  • Abud-Mendoza C, Sturbaum AK, Vazquez-Compean P, Gonz-alez-Amaro R. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol. 1993;20:731–3.
  • Smeenk RJ, van den Brink HG, Brinkman K, Termaat RM, Berden JH, Swaak AJ. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol Int. 1991;11:101–7.
  • Hahn BH, Tsao BP. Antibodies to DNA. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Philadelphia: Lippin-cott Williams & Wilkins; 2002. p. 425–45.
  • Neogi T, Gladman DD, Ibanez D, Urowitz MB. Anti-dsDNA antibody testing by Fan and ELISA techniques is not equivalent. J Rheumatol. 2006;33:1785–8.
  • Steinman AJ, Gladman DD, Ibanez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythe-matosus: frequency and outcome. J Rheumatol. 2010;37:1822–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.